Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here’s Why

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is one of the best cheap biotech stocks to buy now. Guggenheim lifted the price target on Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) to $25 from $20 on February 27, maintaining a Buy rating on the shares and telling investors that it updated its model to reflect fiscal Q4 financials, and continues to be “encouraged” by the company’s goal to achieve profitability in early Q3 of 2026. The rating update came after Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) annou ...